Search DrRajHealth

Saturday, September 24, 2016

Historical analysis examines sugar industry role in heart disease research

Conflict of interest continues in research. Just a week ago the FDA approved Exondys 51 (eteplirsen), the first drug approved to treat patients with Duchenne muscular dystrophy (DMD), driven by high industry lobbying even though the FDA's own scientific panel found no benefit of the drug and recommended against approval. Undoubtedly, big money will be made because those with this devastating disease will see it as an only hope and drive the sales.
from Rajesh Harrykissoon, MD

No comments:

Post a Comment